Xilio Therapeutics

Share on: 
Business Area(s): 

Xilio Therapeutics is developing its proprietary technology to create a new class of ultra-potent IO therapies that are activated selectively within the tumor. Their lead programs have demonstrated potent, tumor-selective activity in preclinical models. XTX201 (IL-2) induces immune activity in tumors without the toxicity seen with non-selective IL-2s, and XTX101 (aCTLA4 mAb) demonstrates improved antitumor activity compared to ipilimumab.

Career Page(s): 
Waltham MA
United States